Delivery Order SPE2DB20D3101-SPE2DB25FRUB9
- Not listed
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with fulfillment performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used primarily in the treatment of systemic lupus...
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on August 28, 2025, with completion anticipated by September 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Benlysta 200 mg/mL auto-injectors, with a ceiling value of $3,082.67 and a completion date of August 29, 2025. This firm fixed-price delivery order is not set-aside and was competitively awarded through the vendor's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical products with a ceiling value of $6,165.34 under a firm fixed-price contract. This non-set-aside delivery order, issued on August 1, 2025, is scheduled for ultimate completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Benlysta 200 mg/ml auto-injectors, with a ceiling value of $3,082.67 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and healthcare solutions provider that serves as...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 28, 2025, with completion expected by September 19, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and represents a competitive award to the pharmaceutical distributor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 20, 2025, with completion scheduled for September 11, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and other autoimmune...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUB9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $12,330.68 and is classified as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta is a biologic medication used primarily for treating systemic lupus erythematosus, representing specialized pharmaceutical support for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen Drug Corp maintains an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The company's position as a prime vendor within the DLA's Medical Supply Chain enables it to fulfill diverse pharmaceutical requirements supporting military healthcare programs and other federal healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 8/29/25 |